A study to characterize the humoral and cellular response following simultaneous immunization with a neo-antigen (KLH) and a recall antigen (tetanus) in healthy volunteers.

Condition: Healthy Volunteers
Sponsor: Centre for Human Drug Research (Netherlands) 
Phase 4

NCT02800811

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

First-in-human, phase I, randomized, double-blind, placebo-controlled, single center study evaluating single and multiple ascending intravenous doses of FR104 in healthy subjects.

Condition: Healthy Volunteers
Sponsor: OSE Immunotherapeutics
Phase 1 

Relates to J Immunol. 2016 Dec 15;197(12):4593-4602. Epub 2016 Nov 14.

NCT02754362

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

Determine the immunogenicity and efficacy of a vaccine composed of tumor associated long synthetic peptides mixed with Montanide ISA-51 VG administered with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose (Poly-ICLC) and bevacizumab in adults with recurrent glioblastoma.

Conditions: Glioblastoma, Glioma
Sponsor: New York University School of Medicine
Collaborator:  Mount Sinai Hospital, New York
Phase 2 

NCT02576145

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

Immune Response to Neoantigen and Recall Antigen in Pediatric Renal Transplant Recipients Treated With the IL-2R Alfa Monoclonal Antibody, Daclizumab (Zenapax®)

Sponsor: Hoffman-La Roche
Condition: Kidney Transplantation
Phase 4 

NCT02545868

A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis

This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).

Condition: Multiple Sclerosis, Relapsing-Remitting

Sponsor: Hoffman-LaRoche
Phase 3 

NCT02334735

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence

Conditions: Melanoma
Sponsor: Nina Bhardwaj
Collaborators: New York University School of Medicine, Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research, Melanoma Research Alliance, Oncovir Inc.
Phase 2

NCT02097849

A Phase 3b Study of BG00012's Effect on Vaccination Response in Subjects With Relapsed Forms of Multiple Sclerosis

A Randomized, Open-Label Study to Assess the Effects of BG00012 on the Immune Response to Vaccination and on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Conditions: Mulitple Sclerosis
Sponsor: Biogen Idec
Phase  III

NCT02079480

Study to Evaluate the Safety, Tolerability, PK, and PD of CD40 in Healthy Subjects (CD40 FIH)

Condition: n/a  (Healthy Adults)
Sponsor: Bristol-Myers Squibb
Phase I

NCT01910662

Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Pruified Protein Derivative (PPD)

Condition: Dermatitis 
Sponsor: GlaxoSmithKline
Phase: 1

NCT01644968

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

Conditions: Advanced Cancer
Sponsors: Providence Health & Services
Phase: I 

Relates to article in Cancer Research